Stage 1: History & Presentation (Timestamp: 3 Weeks Prior to Admission)
A 62-year-old male heart transplant recipient (4 months post-OHT residing in Delhi NCR, on Tacrolimus and Mycophenolate Mofetil) presents to the emergency department with a 3-week history of subacute progressive painful soft tissue masses on his back and right thigh, severe lower extremity myalgias, and difficulty walking.
HPI:
- 3 Weeks Ago: Developed an expanding, painful 12 cm x 6 cm right paraspinal mass on his back following an outdoor rural trip, accompanied by progressive lower extremity myalgias and a shuffling gait.
- 1 Week Ago: Developed additional tender swelling on his right thigh and gluteal region, low-grade fevers (38.1°C), chills, fatigue, and a persistent dry cough. Denies purulent skin drainage, raw meat ingestion, or recent travel outside India.
- PMH & Meds: Ischemic Cardiomyopathy s/p Orthotopic Heart Transplant (4 months prior), Renal Cell Carcinoma s/p Left Nephrectomy, AFib, HTN. Meds: Tacrolimus, Mycophenolate Mofetil, Atovaquone 1500mg daily (for PJP prophylaxis), Apixaban, Nifedipine, Valganciclovir.
- Social History: Retired executive, non-smoker, owns domestic pets, outdoor enthusiast.
Hello, Chief Resident here.
Key Findings: A 62-year-old male, 4 months post-heart transplant on Tacrolimus/MMF, presents with subacute, expanding painful soft tissue masses (paraspinal, thigh), severe myalgias, shuffling gait, fevers, and dry cough post-rural exposure. Crucially, he is on Atovaquone rather than TMP-SMX prophylaxis.
Differential Diagnoses:
1. Disseminated Nocardiosis (45%): High suspicion for cutaneous/subcutaneous abscesses with pulmonary involvement in a severely immunosuppressed host lacking TMP-SMX coverage.
2. Disseminated Fungal Infection (25%): E.g., Cryptococcus, Aspergillus, or endemic mycoses, given outdoor exposure, pulmonary symptoms, and soft tissue involvement.
3. Disseminated Tuberculosis / NTM (15%): High regional prevalence; presents with subacute soft tissue lesions and cough.
4. Bacterial Pyomyositis / Multifocal Abscess (10%): Subacute presentation with severe myalgias and focal soft tissue masses.
5. Post-Transplant Lymphoproliferative Disorder (PTLD) (5%): Soft tissue masses with systemic symptoms early post-OHT.
Prioritized Next Steps:
1. US/CT-guided aspiration or biopsy of soft tissue mass for Gram, modified AFB (Kinyoun), fungal stains, cultures, and histopathology.
2. CT Chest/Abdomen/Pelvis to evaluate pulmonary lesions and extent of tissue involvement.
3. MRI Spine and Right Thigh to assess for pyomyositis, epidural/spinal extension.
4. Brain MRI (contrast-enhanced) to evaluate for subclinical CNS dissemination.
5. Blood cultures (bacterial, fungal, AFB) + Serum Cryptococcal Antigen / Beta-D-glucan.
Hello Attending Consultant here
Top 3 DDx:
1. Disseminated nocardiosis (cutaneous + pulmonary; Atovaquone lacks activity).
2. Invasive mold (Aspergillus/Mucorales) with soft-tissue extension post-rural exposure.
3. Multifocal tuberculous pyomyositis/abscess (endemic, subacute myalgias).
Critique/Improvements:
Plan is solid on imaging/biopsy but under-emphasizes rapid pathogen-directed stains and immuno-modulation. Prioritize modified AFB + Nocardia PCR on aspirate; defer empiric broad antifungals pending stains. Add quantitative CMV PCR and tacrolimus trough immediately—toxicity or over-immunosuppression may drive presentation. Brain MRI is appropriate but obtain before LP if CNS signs emerge. No role for empiric steroids.
Specific points (6):
1. Urgent US-guided FNA with modified Kinyoun, fungal, AFB stains + 16S/ITS PCR.
2. Hold MMF; target lower tacrolimus trough (5–7 ng/mL).
3. CT chest high-res for tree-in-bud/nodules typical of Nocardia.
4. Serum GM, BDG, CrAg; sputum induction for AFB/Nocardia.
5. Orthopedic consult for thigh debridement if abscess confirmed.
6. Empiric TMP-SMX + imipenem only after cultures sent if unstable.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Disseminated nocardiosis (cutaneous/subcutaneous + pulmonary) in a heart transplant recipient with a critical prophylaxis gap.
Top Differentials & Fit:
1. Nocardia (most likely): Subacute painful expanding soft tissue abscesses, dry cough, soil/rural exposure, and intense immunosuppression fit perfectly. Atovaquone covers PJP only—no Nocardia protection.
2. Invasive mold (Aspergillus/Mucorales): Fits immunosuppression and pulmonary–soft tissue spread, but the indolent 3-week course and multiple tender masses are less typical; molds are usually angioinvasive and rapidly progressive.
3. TB/NTM: Endemic in India and subacute, but large acutely painful paraspinal/thigh abscesses are less characteristic.
4. Cryptococcus: Can cause skin and lung disease post-transplant, but painful myositis-like masses argue against it.
5. PTLD: Unlikely—painful, febrile, inflammatory masses are not its typical phenotype.
Key Pivot: The Atovaquone-for-TMP-SMX substitution. This single medication detail reframes the entire case—TMP-SMX prophylaxis normally suppresses Nocardia, Toxoplasma, and Listeria.
Next Move: Urgent image-guided aspiration/biopsy of the paraspinal mass with Gram stain (beaded branching filaments), modified acid-fast stain, cultures, and 16S PCR—plus CT chest and brain MRI to stage dissemination before empiric therapy.
Teaching Pearl: In transplant patients, always audit the prophylaxis regimen—what's missing often reveals the diagnosis.
Stage 2: Physical Examination & Initial Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 38.1°C (febrile), HR 100 bpm (tachycardia), BP 118/87 mmHg, RR 18/min, SpO2 98% room air. Appears uncomfortable, non-toxic. Lungs clear to auscultation. Soft Tissue Exam: Large 12 cm x 6 cm firm, tender, slightly warm mass over right paraspinal back musculature, with additional subcutaneous and intramuscular tender masses in right gluteus and thigh. No peripheral lymphadenopathy.
Initial Laboratory Panel:
- Hemogram: WBC 9.4 x 10³/µL with Neutrophilia (82% PMNs), no eosinophilia; Hb 10.8 g/dL, Platelets 210,000/µL.
- Biochemistry & Inflammatory Markers: Serum Creatinine 1.2 mg/dL, LFTs normal, CPK normal (110 U/L, ruling out primary autoimmune polymyositis), Markedly Elevated ESR (88 mm/hr) and CRP (142 mg/L).
- Infectious & Fungal Serologies: Quantiferon-TB Gold negative, AFB sputum/cultures negative (3x), Serum Fungitell (<31 pg/mL) and Aspergillus Galactomannan negative, Cryptococcal Ag negative, Histoplasma/Coccidioides Ag negative, Blood cultures (2x) negative.
Hello, Chief Resident here.
Updated Key Findings: Febrile, tachycardic, multiple firm, tender paraspinal and lower extremity masses with markedly elevated ESR (88 mm/hr) and CRP (142 mg/L), but normal CPK. Negative systemic fungal markers (BDG, Galactomannan, CrAg), QFT-TB, sputum AFB, and standard blood cultures.
Differential Diagnoses:
1. Disseminated Nocardiosis (55%): Negative fungal markers and routine blood cultures strongly point toward Nocardia, which requires direct tissue biopsy with modified AFB staining; Atovaquone prophylaxis leaves this gap.
2. Non-Tuberculous Mycobacterial (NTM) Soft Tissue Infection (20%): Subacute presentation with cutaneous/muscular abscesses; can be QFT-TB negative.
3. Bacterial Pyomyositis / Multifocal Abscess (15%): E.g., Staphylococcus aureus; normal CPK is consistent with focal abscesses rather than diffuse myositis.
4. Invasive Mucormycosis/Rare Molds (5%): BDG and GM are negative in Mucorales, though course is typically more acute.
5. PTLD (5%): Inflammatory masses can occasionally mimic infection early post-OHT.
Prioritized Next Steps:
1. Urgent image-guided core biopsy/aspiration of paraspinal mass for Gram, Modified Kinyoun, fungal/AFB stains, cultures, and 16S PCR.
2. Contrast-enhanced Brain MRI to screen for asymptomatic CNS dissemination.
3. CT Chest/Abdomen/Pelvis to evaluate pulmonary nodules and muscle involvement.
4. **
Hello Attending Consultant here
Top 3 DDx:
1. Disseminated nocardiosis (soft-tissue + occult pulmonary; prophylaxis gap + negative fungal markers).
2. NTM pyomyositis/abscess (QFT-neg, subacute intramuscular masses).
3. Cryptic bacterial abscesses (e.g., MRSA; neutrophilia, high CRP).
Critique/Improvements:
Resident correctly escalates Nocardia probability and prioritizes biopsy, but plan truncates mid-sentence and underweights immediate immuno-reduction plus CNS staging. Negative BDG/GM/CrAg usefully down-ranks molds/Crypto yet does not exclude Mucorales. Normal CPK appropriately excludes diffuse myositis. Add tacrolimus level and hold MMF now.
Specific points (6):
1. STAT US/CT-guided FNA: Gram, modified Kinyoun, AFB, fungal stains + 16S/hsp65 PCR.
2. Hold MMF; check/reduce tacrolimus trough to 5–7 ng/mL.
3. Contrast brain MRI + CT chest (nodules/cavities) before any empiric Rx.
4. Repeat blood cultures in aerobic bottles held ≥14 d for Nocardia.
5. Ortho consult for possible I&D of thigh/gluteal collections.
6. Empiric TMP-SMX + carbapenem only if septic; await stains.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Disseminated nocardiosis—cutaneous/intramuscular abscesses with likely occult pulmonary and possible CNS involvement.
Top Differentials & Fit:
1. Nocardia (strongest): The negative workup is itself diagnostic evidence—Nocardia does not grow in routine blood cultures, is BDG/GM/CrAg negative, and requires modified acid-fast staining of tissue. Neutrophilia, high CRP, and multifocal painful masses fit perfectly.
2. NTM (e.g., M. abscessus, M. chelonae): QFT-negative, subacute intramuscular abscesses in an immunosuppressed host—plausible, but less likely to cause a 12 cm paraspinal mass.
3. Bacterial pyomyositis (MRSA): Fits neutrophilia and focal abscesses, but negative blood cultures and 3-week indolent course argue against.
4. Mucormycosis: BDG/GM negative by definition, but typically angioinvasive and fulminant—not this indolent.
5. PTLD: Inflammatory markers and masses fit, but fever, neutrophilia, and tenderness favor infection.
Key Pivot: The entirely negative serologic/culture panel paradoxically strengthens Nocardia—an organism invisible to standard diagnostics.
Next Move: Do not delay—proceed to image-guided biopsy with modified Kinyoun stain and 16S PCR, plus brain MRI and CT chest for staging.
Teaching Pearl: A negative workup is not reassuring—it redirects you toward organisms that evade standard tests.
Stage 3: Neuro-Thoracic & Soft Tissue Imaging (Timestamp: Hospital Days 1-3)
Multi-Organ Imaging Workup:
- CT Soft Tissues / Musculature: Multiloculated, septated fluid collections / intramuscular abscesses in the right paraspinal, left gluteal medius, and anterior abdominal wall muscles (severe multifocal pyomyositis/abscesses).
- CT Chest: 2.2 x 1.8 cm posterior apical cavitary lung nodule in the left upper lobe with surrounding tree-in-bud opacities and bronchial wall thickening.
- MRI Brain: 1.4 cm left cerebellar ring-enhancing lesion with extensive surrounding vasogenic edema and mass effect (cerebellar brain abscess).
Hello, Chief Resident here.
Updated Key Findings: Imaging confirms the classic dissemination triad in a heart transplant recipient: a cavitary lung nodule, multifocal multiloculated intramuscular abscesses, and a left cerebellar ring-enhancing brain abscess with mass effect.
Differential Diagnoses:
1. Disseminated Nocardiosis (85%): Pathognomonic triad (pulmonary, CNS, soft tissue) in a severely immunosuppressed host with a TMP-SMX prophylaxis gap.
2. Disseminated Mold (Aspergillus / Mucorales) (10%): Can cause angioinvasive lung, brain, and soft-tissue disease; Mucorales is BDG/GM-negative.
3. Disseminated NTM / Tuberculosis (3%): Can present subacutely with cavitary pulmonary, brain, and intramuscular lesions.
4. Polymicrobial Pyogenic Abscesses (2%): Unlikely to present with this specific subacute triad without positive blood cultures.
Prioritized Next Steps:
1. US/CT-guided aspiration of muscle abscess: STAT Gram (beaded branching rods), modified Kinyoun stain, Nocardia PCR, and cultures.
2. Initiate empiric IV therapy for CNS Nocardia: High-dose TMP-SMX + Meropenem + Linezolid pending species identification/sensitivities.
3. Neurosurgery and Orthopedic consults to evaluate cerebellar mass effect and soft-tissue abscess debridement/drainage.
4. Immunosuppression reduction: Hold MMF and lower Tacrolimus trough target to 5–7 ng/mL.
Hello Attending Consultant here
Top 3 DDx:
1. Disseminated nocardiosis (pulmonary cavitary + multifocal pyomyositis + cerebellar abscess; classic triad + TMP-SMX gap).
2. Invasive mold (Aspergillus/Mucorales; BDG/GM-neg possible for Mucor).
3. Disseminated NTM/TB (endemic, cavitary + CNS + soft tissue).
Critique/Improvements:
Plan correctly locks onto the triad and starts dual/triple coverage plus source control, but over-relies on empiric linezolid (toxicity risk) without first confirming branching filaments on STAT stain. Neurosurgery input is essential given mass effect—steroids only if herniation imminent. Reduce IS more aggressively; add seizure ppx.
Specific points (6):
1. STAT aspirate: Gram/modified AFB stains + 16S PCR before any abx.
2. Empiric high-dose TMP-SMX + imipenem/meropenem (drop linezolid unless confirmed).
3. Urgent NSGY consult for cerebellar edema/mass effect ± steroids/mannitol.
4. Hold MMF; cut tacrolimus to trough 4–6 ng/mL.
5. Ortho I&D of accessible abscesses for source control.
6. Serial neuro checks + EEG if altered; hold apixaban peri-procedure.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Disseminated nocardiosis with the classic triad—cavitary pulmonary nodule, multifocal intramuscular abscesses, and cerebellar brain abscess—in a heart transplant recipient with a TMP-SMX prophylaxis gap.
Top Differentials & Fit:
1. Nocardia (overwhelming): The lung–brain–soft tissue triad in a transplant patient is virtually pathognomonic. Cavitary apical nodule with tree-in-bud, multiloculated muscle abscesses, and a ring-enhancing cerebellar lesion complete the picture.
2. Invasive mold (Aspergillus/Mucorales): Can produce identical tri-organ dissemination, but the 3-week indolent course and negative GM/BDG (though Mucor is seronegative) make this less likely.
3. Disseminated TB/NTM: Endemic and capable of cavitary lung + CNS + soft tissue disease, but negative QFT and sputum AFB argue against.
4. Pyogenic bacterial: Would not typically produce this subacute triad with negative blood cultures.
Key Pivot: The imaging triad transforms a diagnostic puzzle into a near-certainty—Nocardia's tropism for lung, brain, and soft tissue is its signature.
Next Move: STAT aspirate for modified Kinyoun stain and 16S PCR, then immediately start high-dose TMP-SMX + meropenem; urgent neurosurgical evaluation of the cerebellar lesion.
Teaching Pearl: In transplant patients, the lung–brain–skin triad is Nocardia until proven otherwise.
Stage 4: Diagnostic Aspiration, Microscopy & Microbiologic Identification (Timestamp: Hospital Days 3-5)
Diagnostic Interventions & Microbiology:
- Diagnostic Aspiration: Ultrasound-guided percutaneous needle aspiration of the right paraspinal intramuscular abscess yielding purulent fluid.
- Microscopic Examination: Gram stain demonstrates Gram-positive, beaded, branching filamentous bacteria. Modified Kinyoun (Fite-Faraco) stain confirms partially/weakly Acid-Fast Branching Rods.
- Culture & Molecular Identification: Fungal/bacterial cultures at 4 days isolated Nocardia cyriacigeorgica (confirming Disseminated Nocardiosis with cavitary pulmonary, cerebellar CNS, and multifocal intramuscular pyomyositis).
Hello, Chief Resident here.
Updated Key Findings: Aspirate from the paraspinal mass demonstrated Gram-positive, beaded, weakly acid-fast (modified Kinyoun+) branching filaments. Cultures definitively identified Nocardia cyriacigeorgica, confirming Disseminated Nocardiosis with pulmonary, cerebellar, and multifocal soft-tissue involvement.
Differential Diagnoses:
1. Disseminated Nocardiosis (Nocardia cyriacigeorgica) (100%): Confirmed via microbiological staining, culture, and molecular identification.
2. Invasive Mold / NTM / Pyogenic Abscess (0%): Excluded by culture and direct microscopy.
Prioritized Next Steps:
1. Targeted Antimicrobial Combination: Initiate high-dose IV TMP-SMX (15–20 mg/kg/day TMP) plus IV Meropenem (2g q8h), pending species-specific antimicrobial susceptibility testing (broth microdilution).
2. Neurosurgical Monitoring: Serial contrast brain MRI and frequent neuro-checks to manage cerebellar lesion edema and mass effect.
3. Surgical Source Control: Orthopedic consult for incision and drainage/debridement of large, multiloculated intramuscular abscesses.
4. Immunosuppression Adjustment: Hold Mycophenolate Mofetil and lower Tacrolimus trough target (5–7 ng/mL) alongside the heart transplant team.
5. Long-Term Regimen Planning: Plan for a minimum of 6–12 months of therapy with sequential transition to targeted oral agents after clinical improvement.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed disseminated N. cyriacigeorgica (pulmonary-cavitary + CNS + pyomyositis).
2. Occult co-pathogen (rare post-transplant polymicrobial).
3. Drug-resistant Nocardia subspecies (pending AST).
Critique/Improvements:
Plan correctly locks diagnosis and initiates dual therapy + source control/IS reduction, but omits immediate AST-driven de-escalation, TMP-SMX toxicity surveillance, and CNS-specific duration. Meropenem preferred over imipenem for CNS penetration; avoid premature oral switch. Steroids only for impending herniation.
Specific points (6):
1. Send isolate for broth-microdilution AST (TMP-SMX, carbapenem, linezolid, amikacin).
2. High-dose TMP-SMX (15-20 mg/kg TMP) + meropenem 2 g q8h; add linezolid if severe.
3. Urgent ortho I&D of multiloculated collections; NSGY for cerebellar mass effect.
4. Hold MMF; tacrolimus trough 4-6 ng/mL; daily Cr/K+ monitoring.
5. Serial brain MRI q2wk; minimum 12 mo total therapy for CNS disease.
6. Seizure prophylaxis; hold apixaban peri-procedure.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Confirmed disseminated Nocardia cyriacigeorgica—cavitary pulmonary, cerebellar CNS, and multifocal intramuscular disease in a heart transplant recipient with a TMP-SMX prophylaxis gap.
Top Differentials & Fit:
1. N. cyriacigeorgica (confirmed): Beaded, branching, weakly acid-fast filaments on Gram and modified Kinyoun stains with culture identification close the case. This species is notable for variable antimicrobial susceptibility—AST is essential.
2. Co-pathogen (low): Polymicrobial infection is possible post-transplant but unlikely given the classic triad and clean microbiology.
3. Drug-resistant Nocardia: N. cyriacigeorgica can harbor resistance to TMP-SMX and carbapenems—pending broth microdilution AST will guide de-escalation.
Key Pivot: The modified Kinyoun stain. This single bedside test—often overlooked—distinguished Nocardia from all mimics and directed therapy before culture confirmation.
Next Move: Send isolate for broth microdilution AST; continue high-dose TMP-SMX + meropenem; pursue surgical drainage of accessible abscesses; serial brain MRI; plan minimum 12 months of therapy for CNS disease.
Teaching Pearl: N. cyriacigeorgica is the most common Nocardia species in transplant recipients—always request species-level identification and susceptibility testing, as resistance patterns vary widely.
Stage 5: Final Unifying Diagnosis & Clinical Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Disseminated Nocardiosis (Nocardia cyriacigeorgica) presenting with cavitary pulmonary nodules, cerebellar brain abscess, and multifocal intramuscular pyomyositis in a post-transplant patient on non-Bactrim (Atovaquone) prophylaxis.
Treatment Plan:
- Induction Antimicrobial Therapy: Initiated on triple combination therapy with IV Imipenem-Cilastatin (500mg Q6H) + IV Ceftriaxone (2g Q12H) + High-Dose Oral TMP-SMX (Bactrim DS 2 tabs TID) (with temporary adjustment to Linezolid/Ceftriaxone due to TMP-SMX hyperkalemia/AKI), along with modest reduction of Tacrolimus.
- Outcome: Rapid clinical resolution of fever and muscle pain within 7 days, complete radiologic resolution of soft tissue abscesses, marked regression of brain and lung lesions, and planned 12-month targeted antimicrobial therapy.
Hello, Chief Resident here.
Updated Key Findings: Microbiologic confirmation of Disseminated Nocardia cyriacigeorgica manifesting as the classic triad—cavitary lung nodule, cerebellar brain abscess, and multifocal intramuscular pyomyositis—precipitated by a critical prophylaxis gap (Atovaquone substituted for TMP-SMX).
Final Diagnosis & Probability:
1. Disseminated Nocardiosis (Nocardia cyriacigeorgica): 100% (Confirmed via modified Kinyoun stain and culture identification).
Case Summary & Management:
This case underscores a fundamental principle in transplant medicine: audit the prophylaxis regimen. Switching from TMP-SMX to Atovaquone left this patient vulnerable to Nocardia, Toxoplasma, and Listeria. Rapid identification via bedside modified acid-fast staining allowed prompt initiation of targeted combination therapy.
Next Steps & Maintenance Plan:
1. Antimicrobial Duration: Complete a minimum of 12 months of directed therapy given CNS dissemination.
2. Monitoring: Serial contrast brain MRI every 2–3 months to ensure complete resolution; monitor renal function, potassium, and blood counts closely if rechallenging with TMP-SMX or prolonged Linezolid.
3. Immunosuppression: Maintain reduced immunosuppression (tacrolimus trough 5–7 ng/mL) in close coordination with the heart transplant team.
4. Prophylaxis: Resume secondary Nocardia/PJP prophylaxis upon treatment completion.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed disseminated N. cyriacigeorgica (triad + stain/culture).
2. TMP-SMX-resistant subspecies (hyperkalemia forced switch; AST critical).
3. Occult co-infection or IRIS post-IS reduction (rare).
Critique/Improvements:
Solid confirmation and induction with source control implied, but regimen suboptimal—imipenem has variable CNS activity vs meropenem; ceftriaxone adds little without AST. Linezolid switch appropriate for AKI/hyperK but mandates weekly CBC/neuropathy checks. Modest tacrolimus cut insufficient; hold MMF fully. 12-mo duration correct for CNS, yet lacks explicit secondary prophylaxis plan and serial imaging cadence.
Specific points (6):
1. Obtain/report broth microdilution AST immediately to de-escalate.
2. Prefer meropenem 2g q8h over imipenem for CNS penetration.
3. Monitor linezolid toxicity (CBC, lactate, neuropathy) q1–2 wk.
4. Hold MMF; target tacrolimus 4–6 ng/mL with transplant team.
5. Serial brain/chest MRI at 4–6 wk then q3 mo until resolution.
6. Secondary TMP-SMX prophylaxis post-therapy; educate on soil exposure.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Disseminated Nocardia cyriacigeorgica—cavitary pulmonary, cerebellar CNS, and multifocal intramuscular disease—confirmed by modified Kinyoun stain and culture, driven by a TMP-SMX prophylaxis gap.
Top Differentials & Fit:
1. N. cyriacigeorgica (confirmed): The triad, stain morphology, and culture identification close the case. This species is the most common Nocardia in transplant recipients and carries variable susceptibility—AST remains essential.
2. TMP-SMX resistance: Hyperkalemia/AKI forced a switch to linezolid/ceftriaxone; pending AST will determine whether this was toxicity or true resistance.
3. IRIS/co-infection: Unlikely given rapid clinical improvement, but monitor as immunosuppression is reduced.
Key Pivot: The Atovaquone-for-TMP-SMX substitution. This single medication change created the vulnerability; the modified Kinyoun stain provided the answer.
Next Move: Obtain broth microdilution AST to de-escalate; prefer meropenem over imipenem for CNS penetration; monitor linezolid toxicity; serial brain MRI; complete 12 months of therapy; resume secondary prophylaxis.
Teaching Pearl: In transplant medicine, the prophylaxis regimen is part of the differential diagnosis—what's missing often reveals the pathogen.